On behalf of a terrific team of investigators (@BGarmezy @KotechaMD @DrKarieRuncie @BraunMDPhD et al), very proud to present the 1st data for XmAb819, a first-in-class ENPP3 x CD3 bispecific in patients with #kidneycancer. We have long needed new targets beyond #VEGF-axis &

EV+P is a pivotal regimen in la/mUC & 🔜 expanding to MIUC. Proactive AE monitoring, pt 📚, & multidisciplinary collaboration are critical to optimizing safety & efficacy. 🚨 SJS/TEN, DKA, ILD 📋 Baseline & ongoing monitoring for AEs 🔑 Early ID & proactive dose modifications ⬇️

ESMO25: Lenvatinib + everolimus vs cabozantinib in metastatic clear cell RCC post–PD-1: median PFS of 15.7 months vs 10.2 months (HR = 0.51) First randomized head-to-head comparison of common 2L treatments, according to presenter @OncHahn #KidneyCancer https://t.co/pYG9oLAPqR

@mwschoen @OncHahn @neerajaiims @TiansterZhang @urotoday @AlanBryce9 @charlesryanmd @DrChoueiri @ChadTangMD Agree. yet there is clearly something important about this pathway, and we may be getting closer to targeting it successfully - now may be the time to refine the biomarker and dosing strategy.

Thorough, insightful review of PARP inhibitors in #prostatecancer from @neerajaiims @huntsmancancer - monotherapy & rationale for combos. Important to test our patients for HRR alterations! @myESMO @OncoAlert #ESMO25 #ESMOAmbassadors

As always, a masterclass in #prostatecancer from @neerajaiims @huntsmancancer. At #ESMO25, he covered tx directed at homologous repair combinations, citing foundational work from @quimmateo, #DrMahaHussain, @AlanBryce9 & so many others, then leading into the pivotal P3

An insightful story about AVPC by @aaparicioMD: how to interpret the molecular alterations and how we’ve been treating them @MDAndersonNews #ESMO25

Comprehensive discussion about targeting HRR alterations with PARP inhibitors in metastatic prostate cancer by @neerajaiims #ESMO25

Outstanding discussion by @AzadOncology on #PSMAaddition at #ESMO25 👉highlighting the need for a personalized approach in mHSPC #ProstateCancer 👉 pt selection, toxicity vigilance, & that not all pts need Lu-177 or 6 cycles 👉precision, not over-treatment. @OncoAlert @UroToday

Capitello-281 evaluated Akt inhibitor in PTEN deficient mHSPC. 6000 pts screened to randomize ~ 1K. Modest rPFS benefit, OS immature. Nice to see biomarker approach, TBD if it moves the needle enough to justify the toxicity and identification

Updated results from PRESTO evaluating apalutamide in BCR. Doublet and triplet arms did not significantly improve MFS. Time to CRPC and eugonad PSA PFS were significantly improved.

Fantastic talk by @DrPaulNguyen #ESMO25 👉result of ph3 Enzarad trial👉Addition of ENZA to ADT + radiation did not improve MFS in all high risk localized, the primary endpoint. However, node+ on CT/MRI pts derived benefit, like Stampede trial @OncoAlert @urotoday @PCF_Science

Breaking news from #ESMO25 in Berlin 👉Randomized trial of Pluvicto/Lu-177 vs. docetaxel (DOC) in 199 pts with mCRPC #prostatecancer 👉progressing after ARPI therapy👉Similar PFS (primarily endpoint) but higher OS with docetaxel👇#KimChi #ESMO25 @OncoAlert @urotoday @PCF_Science

Congratulations to @OncHahn, @JadChahoud and the entire team on completing this randomized investigator-initiated multicenter trial. Many thought it was impossible for such a comparison to be completed but you turned it into reality. @neerajaiims @PGrivasMDPhD @montypal

#LenCabo: a randomized phase ii multicenter trial of lenvatinib plus everolimus vs cabozantinib in patients with metastatic clear cell #RCC that progressed on PD-1 immune checkpoint inhibition. Presented by @OncHahn @MDAndersonNews. #ESMO25 written coverage by @RKSayyid

Wonderful talk by @PGrivasMDPhD on neoadj #bladdercancer treatment w updates #NIAGARA , role of ctDNA and ongoing neoadjuvant/adjuvant trials👉his take home message for our clinical practice. #ESMO25 #ESMOAmbassador @OncoAlert @myESMO

Our poster assessing prognostic scores in 1L EVP pts. Belmont score: liver mets, ECOG >0, and Hgb<10 was best for predicting OS/PFS . Thanks to UNITE @koshkin85 for this opportunity and incredible mentorship by @DocMattCampbell and @OAlhalabiMD

Results from a trial found a targeted therapy combination improved outcomes for patients with metastatic clear-cell renal carcinoma whose disease progressed following immunotherapy. Learn more about the data presented at #ESMO25: https://t.co/ZNeGrUBctl @OncHahn #EndCancer

📢 #ESMO25 concomitant paper: results from the LenCabo phase II trial of lenvatinib + everolimus vs cabozantinib post PD-1 ICI in metastatic ccRCC @OncHahn https://t.co/4EmwlwVhqE

Excited to see LenCabo published concomitant in @Annals_Oncology Plan to post a full tweetorial summarizing our results later @PavlosMsaouel